HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria.

Abstract
The efficacy of terfenadine, a nonsedating H1 antihistamine, in the management of chronic idiopathic urticaria was compared with chlorpheniramine and placebo in a parallel multicenter trial. Subjects with symptoms of hives for 3 days per week for at least 6 weeks were initially screened and admitted if no identifiable cause for symptoms could be determined. Patients entered a single-blind placebo period, and if hives of moderate severity were present for at least 3 days during the week, they were randomly assigned in a double-blind fashion to take terfenadine, 60 mg twice daily, chlorpheniramine, 4 mg three times a day, or placebo for 6 weeks. Data were analyzed for 122 patients. Those patients receiving both active treatments noted significant improvement in symptoms: pruritus, redness, number of hives, and waking hours during which hives were present, at the end of the first day of therapy. Symptom control by terfenadine was statistically superior to placebo during all 6 weeks, as rated by both patients and investigators. However, statistical significance was not achieved for chlorpheniramine at all observation points. Diphenhydramine was permitted as a relief medication for refractory symptoms and was taken by 52% of subjects receiving placebo, 26% taking chlorpheniramine, and only 9% of patients who were receiving terfenadine. In addition to providing superior symptom control, terfenadine caused less drowsiness and fatigue than chlorpheniramine. Terfenadine is a useful therapeutic agent for primary management of chronic idiopathic urticaria.
AuthorsJ A Grant, D I Bernstein, C E Buckley, T Chu, R W Fox, R E Rocklin, W F Schoenwetter, S L Spector, C T Stafford, J E Stroh Jr
JournalThe Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 81 Issue 3 Pg. 574-9 (Mar 1988) ISSN: 0091-6749 [Print] United States
PMID3126220 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Benzhydryl Compounds
  • Placebos
  • Chlorpheniramine
  • Terfenadine
Topics
  • Adolescent
  • Adult
  • Benzhydryl Compounds (therapeutic use)
  • Chlorpheniramine (therapeutic use)
  • Chronic Disease
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Placebos
  • Terfenadine
  • Urticaria (drug therapy, etiology, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: